

Regeneron - Eylea's Growth Potential and Pipeline is Lucrative Enough!

<https://marketpublishers.com/r/R7BFB0362B1EN.html>

Date: October 2013

Pages: 7

Price: US\$ 140.00 (Single User License)

ID: R7BFB0362B1EN

Abstracts

Regeneron's (REGN) growth trajectory will be sustained by the sales and upcoming label expansion of Eylea (aflibercept, VEGF-Trap Eye, L, wet-AMD, Central Retinal Vein Occlusion – CRVO, partnered with Bayer for ex-US) in Diabetic Macular Edema (DME) and myopic choroidal neovascularization (mCNV) and promise of the late-stage pipeline esp. anti-PCSK9 mAb, Alirocumab (REGN727, PhIII, Hypercholesterolemia, partnered with Sanofi). Not undermining the future potential of ... For more detail, please read our report released on Oct. 9, 2013 on REGN, titled, "Eylea's Growth Potential and Pipeline is Lucrative Enough!"

I would like to order

Product name: Regeneron - Eylea's Growth Potential and Pipeline is Lucrative Enough!

Product link: <https://marketpublishers.com/r/R7BFB0362B1EN.html>

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R7BFB0362B1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970